Promising Outlook - US Cancer Vaccine Market
Cancer involves abnormal and uncontrolled cell growth which may spread to other parts of the body as well. According to GLOBOCAN, in 2015, approximately 15.2 Million incidences of cancer were registered all across the globe. Out of total, US accounted for approximately 1.7 Million incidences of this deadly disease. Cancer is also one of the leading causes of mortality. Traditional treatment options, such as surgery, chemotherapy and radiotherapy, have several drawbacks such as hair loss, abnormal blood cell count and nausea. One of the major drawbacks of traditional cancer treatment therapies is the risk of remission in patient.
Owing to all these shortcomings, researchers are developing novel treatment options, such as cancer vaccines, for this disease. Cancer vaccines have always been considered as high potential method for preventing and treating cancer even though they have not been able to achieve their expected sales. However, the market for these vaccines is expected to witness decent growth in the coming years due to the launch of new cancer vaccines and increasing awareness among people about this treatment option.
According to the RNCOS report entitled “Promising Outlook - US Cancer Vaccine Market”, the US is largest market for cancer vaccines amongst all the geographic regions worldwide. The report provides information about the current and future scenario of this market. The report also highlights the major drivers, such as increasing cancer incidences in the country, rising awareness, and strong pipeline, for the US Cancer Vaccines Market. Furthermore, the report also gives information related to the commercially available cancer vaccines. It also covers the restraints hampering the growth of the market, and future opportunities.
On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounted for the largest share in 2017. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline.
Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent.
The prominent players in US Cancer Vaccines Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the US Cancer Vaccines Market.
Owing to all these shortcomings, researchers are developing novel treatment options, such as cancer vaccines, for this disease. Cancer vaccines have always been considered as high potential method for preventing and treating cancer even though they have not been able to achieve their expected sales. However, the market for these vaccines is expected to witness decent growth in the coming years due to the launch of new cancer vaccines and increasing awareness among people about this treatment option.
According to the RNCOS report entitled “Promising Outlook - US Cancer Vaccine Market”, the US is largest market for cancer vaccines amongst all the geographic regions worldwide. The report provides information about the current and future scenario of this market. The report also highlights the major drivers, such as increasing cancer incidences in the country, rising awareness, and strong pipeline, for the US Cancer Vaccines Market. Furthermore, the report also gives information related to the commercially available cancer vaccines. It also covers the restraints hampering the growth of the market, and future opportunities.
On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounted for the largest share in 2017. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline.
Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent.
The prominent players in US Cancer Vaccines Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the US Cancer Vaccines Market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. CANCER STATISTICS BY DEMOGRAPHICS
3.1 Prevalence, Incidences and Mortality
3.2 Leading States by Incidences
3.3 Leading Cancers by Incidences
3.3.1 Male Cancer Incidences
3.3.2 Female Cancer Incidences
3.3.3 Children Cancer Incidences
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Rising Cancer Incidences
4.1.2 Ability to Reduce Healthcare Expenditure
4.1.3 Rising Awareness
4.1.4 Patient Assistance Programs
4.1.5 Government Initiatives
4.1.6 Strong Pipeline
4.1.7 Technological Advancements
4.2 Restraints
4.2.1 High Cost of Cancer Vaccines
4.2.2 Side-Effects of Cancer Vaccines
4.2.3 Vaccine Supply Shortages
4.2.4 Insurance Issues Related to Cancer Vaccination
4.3 Opportunities
4.3.1 Therapeutic Cancer Vaccines
4.3.2 Adjuvant Cancer Vaccines
5. CANCER VACCINES MARKET OUTLOOK
5.1 Key Product Analysis
5.1.1 Provenge
5.1.1.1 Market Analysis
5.1.2 T-Vec/Imlygic
5.1.2.1 Market Analysis
5.1.3 HPV Vaccine
5.1.3.1 Gardasil
5.1.3.1.1 Market Analysis
5.1.3.2 Cervarix
5.1.3.2.1 Market Analysis
5.1.4 HBV Vaccines
5.1.4.1 Engerix-B & Twinrix
5.1.4.1.1 Market Analysis
5.1.4.2 Recombivax HB
5.1.4.2.1 Market Analysis
5.1.4.3 Pediarix/ Infanrix
5.1.4.3.1 Market Analysis
6. CANCER VACCINES MARKET BY CANCER TYPE
7. CANCER VACCINE MARKET BY APPLICATION
8. POTENTIAL CANCER VACCINE CANDIDATES: AN OPPORTUNITY ASSESSMENT
8.1 Prophylactic Vaccine
8.2 Therapeutic Vaccine
8.2.1 Prostate Cancer
8.2.2 Breast Cancer
8.2.3 Lung Cancer
8.2.4 Colorectal Cancer
9. US PATENT ANALYSIS
9.1 Patents by Year
9.2 Patents by Category
9.2.1 Utility Patents
9.2.2 Design Patents
9.2.3 Plant Patents
9.3 Patents by Company
9.4 Patents by Assignee Type
9.4.1 By Assignee Name
9.4.2 By Assignee State
10. REGULATORY ENVIRONMENT
10.1 Vaccine Approval Process
10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
10.2.1 Considerations for both Early and Late Phase Clinical Trials
10.2.1.1 Patient Population
10.2.1.2 Monitoring the Immune Response
10.2.1.3 Biomarkers as Evidence of Efficacy
10.2.1.4 Adjuvants Used to Stimulate Immune Response
10.2.1.5 Multi-antigen Vaccines
10.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines
10.2.1.7 Concomitant and Subsequent Therapies
10.2.2 Considerations for Early Phase Clinical Trials
10.2.2.1 Starting Dose and Dosing Schedule
10.2.2.2 Booster and Maintenance Therapy
10.2.2.3 Dose Escalation
10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development
10.2.3 Considerations for Late Phase Clinical Trials
10.2.3.1 Safety Profile from Early Phase Clinical Trials
10.2.3.2 Endpoints
10.2.3.3 Statistical Issues
10.2.3.4 Control Issues
10.2.3.5 Delayed Vaccine Effect
10.2.3.6 Autologous Vaccine Trials
10.2.3.7 Accelerated Approval Regulations
11. COMPETITIVE LANDSCAPE
12. COMPANY PROFILES
12.1 Merck & Co., Inc.
12.2 GlaxoSmithKline plc.
12.3 Dendreon Pharmaceuticals LLC
12.4 Amgen Inc.
2. RESEARCH METHODOLOGY
3. CANCER STATISTICS BY DEMOGRAPHICS
3.1 Prevalence, Incidences and Mortality
3.2 Leading States by Incidences
3.3 Leading Cancers by Incidences
3.3.1 Male Cancer Incidences
3.3.2 Female Cancer Incidences
3.3.3 Children Cancer Incidences
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Rising Cancer Incidences
4.1.2 Ability to Reduce Healthcare Expenditure
4.1.3 Rising Awareness
4.1.4 Patient Assistance Programs
4.1.5 Government Initiatives
4.1.6 Strong Pipeline
4.1.7 Technological Advancements
4.2 Restraints
4.2.1 High Cost of Cancer Vaccines
4.2.2 Side-Effects of Cancer Vaccines
4.2.3 Vaccine Supply Shortages
4.2.4 Insurance Issues Related to Cancer Vaccination
4.3 Opportunities
4.3.1 Therapeutic Cancer Vaccines
4.3.2 Adjuvant Cancer Vaccines
5. CANCER VACCINES MARKET OUTLOOK
5.1 Key Product Analysis
5.1.1 Provenge
5.1.1.1 Market Analysis
5.1.2 T-Vec/Imlygic
5.1.2.1 Market Analysis
5.1.3 HPV Vaccine
5.1.3.1 Gardasil
5.1.3.1.1 Market Analysis
5.1.3.2 Cervarix
5.1.3.2.1 Market Analysis
5.1.4 HBV Vaccines
5.1.4.1 Engerix-B & Twinrix
5.1.4.1.1 Market Analysis
5.1.4.2 Recombivax HB
5.1.4.2.1 Market Analysis
5.1.4.3 Pediarix/ Infanrix
5.1.4.3.1 Market Analysis
6. CANCER VACCINES MARKET BY CANCER TYPE
7. CANCER VACCINE MARKET BY APPLICATION
8. POTENTIAL CANCER VACCINE CANDIDATES: AN OPPORTUNITY ASSESSMENT
8.1 Prophylactic Vaccine
8.2 Therapeutic Vaccine
8.2.1 Prostate Cancer
8.2.2 Breast Cancer
8.2.3 Lung Cancer
8.2.4 Colorectal Cancer
9. US PATENT ANALYSIS
9.1 Patents by Year
9.2 Patents by Category
9.2.1 Utility Patents
9.2.2 Design Patents
9.2.3 Plant Patents
9.3 Patents by Company
9.4 Patents by Assignee Type
9.4.1 By Assignee Name
9.4.2 By Assignee State
10. REGULATORY ENVIRONMENT
10.1 Vaccine Approval Process
10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
10.2.1 Considerations for both Early and Late Phase Clinical Trials
10.2.1.1 Patient Population
10.2.1.2 Monitoring the Immune Response
10.2.1.3 Biomarkers as Evidence of Efficacy
10.2.1.4 Adjuvants Used to Stimulate Immune Response
10.2.1.5 Multi-antigen Vaccines
10.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines
10.2.1.7 Concomitant and Subsequent Therapies
10.2.2 Considerations for Early Phase Clinical Trials
10.2.2.1 Starting Dose and Dosing Schedule
10.2.2.2 Booster and Maintenance Therapy
10.2.2.3 Dose Escalation
10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development
10.2.3 Considerations for Late Phase Clinical Trials
10.2.3.1 Safety Profile from Early Phase Clinical Trials
10.2.3.2 Endpoints
10.2.3.3 Statistical Issues
10.2.3.4 Control Issues
10.2.3.5 Delayed Vaccine Effect
10.2.3.6 Autologous Vaccine Trials
10.2.3.7 Accelerated Approval Regulations
11. COMPETITIVE LANDSCAPE
12. COMPANY PROFILES
12.1 Merck & Co., Inc.
12.2 GlaxoSmithKline plc.
12.3 Dendreon Pharmaceuticals LLC
12.4 Amgen Inc.
LIST OF FIGURES:
Figure 3-1: Cancer Incidences (Million), 2015 & 2025
Figure 3-2: Cancer Mortality (Million), 2015 & 2025
Figure 3-3: Incidences by Cancer Type (%), 2018
Figure 3-4: States with Highest Cancer Incidences, 2018
Figure 5-1: Global - Cancer Vaccine Market (Million US$), 2016-2023
Figure 5-2: US - Cancer Vaccine Market (Million US$), 2016-2023
Figure 5-3: Share of US in Global Cancer Vaccine Market (%), 2017
Figure 5-4: US - Cancer Vaccine Market by Product Type (%), 2017
Figure 5-5: US - Provenge Market (Million US$), 2013-2017
Figure 5-6: Share of US in Global Imlygic Sales (%), 2017
Figure 5-7: Global - Gardasil Market (Million US$), 2013-2017
Figure 5-8: US - Gardasil Market (Million US$), 2013-2017
Figure 5-9: Share of US in Global Gardasil Sales (%), 2017
Figure 5-10: Global - Cervarix Market (Million US$), 2013-2017
Figure 5-11: US - Cervarix Market (Million US$), 2013-2017
Figure 5-12: Share of US in Global Cervarix Sales (%), 2017
Figure 5-13: Global - Engerix-B & Twinrix Market (Million US$), 2013-2017
Figure 5-14: US - Engerix-B & Twinrix Market (Million US$), 2013-2017
Figure 5-15: Share of US in Global Engerix-B & Twinrix Sales (%), 2017
Figure 5-16: Global - Recombivax HB Market (Million US$), 2013-2017
Figure 5-17: US - Recombivax HB Market (Million US$), 2013-2017
Figure 5-18: Share of US in Global Recombivax HB Sales (%), 2017
Figure 5-19: Global - Pediarix/Infanrix Market (Million US$), 2013-2017
Figure 5-20: US - Pediarix/ Infanrix Market (Million US$), 2013-2017
Figure 5-21: Share of US in Global Pediarix/Infanrix Sales (%), 2017
Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2017
Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2016-2023
Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2016-2023
Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2016-2023
Figure 7-1: US - Cancer Vaccine Market by Application (%), 2017
Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2016-2023
Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2016-2023
Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2017
Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2017
Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2017
Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2017
Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2017
Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2017
Figure 12-1: Merck & Co., Inc. - Breakup of Sales by Business Segment (%), 2017
Figure 12-2: Merck & Co., Inc. - Breakup of Sales by Geography (%), 2017
Figure 12-3: GlaxoSmithKline - Breakup of Group Turnover by Business Segment (%), 2017
Figure 12-4: GlaxoSmithKline - Breakup of Group Turnover by Geography (%), 2017
Figure 12-5: Amgen Inc. - Breakup of Revenue by Geography (%), 2017
Figure 3-1: Cancer Incidences (Million), 2015 & 2025
Figure 3-2: Cancer Mortality (Million), 2015 & 2025
Figure 3-3: Incidences by Cancer Type (%), 2018
Figure 3-4: States with Highest Cancer Incidences, 2018
Figure 5-1: Global - Cancer Vaccine Market (Million US$), 2016-2023
Figure 5-2: US - Cancer Vaccine Market (Million US$), 2016-2023
Figure 5-3: Share of US in Global Cancer Vaccine Market (%), 2017
Figure 5-4: US - Cancer Vaccine Market by Product Type (%), 2017
Figure 5-5: US - Provenge Market (Million US$), 2013-2017
Figure 5-6: Share of US in Global Imlygic Sales (%), 2017
Figure 5-7: Global - Gardasil Market (Million US$), 2013-2017
Figure 5-8: US - Gardasil Market (Million US$), 2013-2017
Figure 5-9: Share of US in Global Gardasil Sales (%), 2017
Figure 5-10: Global - Cervarix Market (Million US$), 2013-2017
Figure 5-11: US - Cervarix Market (Million US$), 2013-2017
Figure 5-12: Share of US in Global Cervarix Sales (%), 2017
Figure 5-13: Global - Engerix-B & Twinrix Market (Million US$), 2013-2017
Figure 5-14: US - Engerix-B & Twinrix Market (Million US$), 2013-2017
Figure 5-15: Share of US in Global Engerix-B & Twinrix Sales (%), 2017
Figure 5-16: Global - Recombivax HB Market (Million US$), 2013-2017
Figure 5-17: US - Recombivax HB Market (Million US$), 2013-2017
Figure 5-18: Share of US in Global Recombivax HB Sales (%), 2017
Figure 5-19: Global - Pediarix/Infanrix Market (Million US$), 2013-2017
Figure 5-20: US - Pediarix/ Infanrix Market (Million US$), 2013-2017
Figure 5-21: Share of US in Global Pediarix/Infanrix Sales (%), 2017
Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2017
Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2016-2023
Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2016-2023
Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2016-2023
Figure 7-1: US - Cancer Vaccine Market by Application (%), 2017
Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2016-2023
Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2016-2023
Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2017
Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2017
Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2017
Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2017
Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2017
Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2017
Figure 12-1: Merck & Co., Inc. - Breakup of Sales by Business Segment (%), 2017
Figure 12-2: Merck & Co., Inc. - Breakup of Sales by Geography (%), 2017
Figure 12-3: GlaxoSmithKline - Breakup of Group Turnover by Business Segment (%), 2017
Figure 12-4: GlaxoSmithKline - Breakup of Group Turnover by Geography (%), 2017
Figure 12-5: Amgen Inc. - Breakup of Revenue by Geography (%), 2017
LIST OF TABLES:
Table 3-1: Top 10 Cancer Incidences in Males (2018)
Table 3-2: Top 10 Cancer Incidences in Females (2018)
Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2018)
Table 4-1: Cancer Incidences (Million), 2015, 2020 & 2025
Table 8-1: Cancers with High Linkage to Virus and Bacteria
Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials
Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials
Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials
Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials
Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials
Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials
Table 12-1: Merck & Co., Inc. - Key Financials (Million US$), 2015-2017
Table 12-2: Merck & Co., Inc. - Product Portfolio
Table 12-3: Merck & Co., Inc. - Cancer Vaccines in Pipeline
Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2015-2017
Table 12-5: GlaxoSmithKline - Product Portfolio
Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline
Table 12-7: Dendreon Pharmaceuticals LLC - Product Portfolio
Table 12-8: Amgen Inc. - Key Financials (Million US$), 2015-2017
Table 12-9: Amgen Inc. - Product Portfolio
Table 3-1: Top 10 Cancer Incidences in Males (2018)
Table 3-2: Top 10 Cancer Incidences in Females (2018)
Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2018)
Table 4-1: Cancer Incidences (Million), 2015, 2020 & 2025
Table 8-1: Cancers with High Linkage to Virus and Bacteria
Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials
Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials
Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials
Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials
Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials
Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials
Table 12-1: Merck & Co., Inc. - Key Financials (Million US$), 2015-2017
Table 12-2: Merck & Co., Inc. - Product Portfolio
Table 12-3: Merck & Co., Inc. - Cancer Vaccines in Pipeline
Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2015-2017
Table 12-5: GlaxoSmithKline - Product Portfolio
Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline
Table 12-7: Dendreon Pharmaceuticals LLC - Product Portfolio
Table 12-8: Amgen Inc. - Key Financials (Million US$), 2015-2017
Table 12-9: Amgen Inc. - Product Portfolio
